| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Although the number of pancreatic cancer cases has been increasing in recent years due to the aging of the population and changes in dietary habits, early diagnosis of pancreatic cancer is difficult and the establishment of effective preventive methods is required in the future. In this study, the chemopreventive effect of metformin in pancreatic cancer was examined by organoid analysis, animal experiments using mouse models of pancreatic carcinogenesis, and clinical pilot studies in pancreatic cancer patients. The aim is to elucidate the mechanism of action of metformin by conducting gene expression analysis and protein analysis, and to realize chemoprevention of pancreatic cancer by metformin.
|
